Description

Nefiracetam Nootropic Powder

 

 

 

CAS Number	77191-36-7
Other Names	77191-36-7, Translon, DM 9384, DMPPA, Nefiracetamum, Motiva, DM-9384, DZL-221, CCRIS 6729, NSC-759830, BRN 6848330, UNII-1JK12GX30N
IUPAC Name	N-(2,6-dimethylphenyl)-2-(2-oxopyrrolidin-1-yl)acetamide
Molecular Formula	C₁₄H₁₈N₂O₂
Molecular Weight	246.3
Purity	≥99% Pure (LC-MS)
Liquid Availability	30mL liquid (100mg/mL, 3000mg bottle)
Powder Availability	10 grams
Gel Availability	N/A
Storage	Store in cool dry environment, away from direct sunlight.
Terms	All products are for laboratory developmental research USE ONLY. Products are not for human consumption.

 

What is Nefiracetam?

Nefiracetam is categorized as a nootropic agent that is a derivative of pyrrolidone. Recently conducted animal-based research has found that the compound facilitates cognitive function and decreases drug-induced amnesia. The proposed mechanism of action of nefiracetam is related to the ability of pyrrolidone derivatives to activate dopaminergic, cholinergic, and glutamatergic neurotransmitter systems. Activating these systems results in increased release of neurotransmitters from the presynaptic terminals and the improvement of neurotransmitter release from the postsynaptic terminals. Current research regarding the nootropic is focused on its ability to treat cognitive impairments related to traumatic injuries and neurodegeneration [1].

 

Main Research Findings

1) Based on the results of the Morris water maze test, treatment with nefiracetam has the potential to effectively treat cognitive dysfunction related to traumatic brain injury.

2) When assessing eyeblink classical conditioning as a representation of behavioral paradigm and cognitive functioning in rabbits, administration of nefiracetam was shown to attenuate learning deficits in aged animals.

 

Selected Data

1) The experiment conducted by the research team of DeFord et al examined the ability of nefiracetam to facilitate the recovery of cognitive functioning after a traumatic brain injury was induced in the test subjects. For the purpose of this study 39 adult male Sprague-Dawley rats weight 300-350 grams were utilized for testing. The rats were maintained under standard conditions with ad libitum access to food and water. All subjects were randomly assigned to 5 different groups included: untreated sham-injury, sham-injury + 9 mg/kg of nefiracetam, injured-saline, injured + 3 mg/kg of nefiracetam, injured + 9 mg/kg of nefiracetam. The nootropic was orally administered to the animals between 9:00 and 11:00 AM from day 1 to day 15 after induction of the brain injury. Cognitive task testing took place 30 minutes after the animals were treated with nefiracetam considering concentration levels peak within 2 hours of administration [1].

In order to induce experimental brain injury a fluid percussion device consisting of a cylindrical reservoir measuring 60 cm in length and 4.5 cm in diameter was used. Surgical preparation began by fitting one end of the device with a Luer-Lock fitting that was then implanted over the exposed dura mater of the rats. The rats were prepared for the surgery 24 hours prior and were administered 54 mg/kg of sodium pentobarbital for anesthetic purposes. A craniectomy was performed and burr holes were placed so a modified Luer-Lock syringe hub could be placed over the exposed and intact dura mater. The syringe was bonded to the dura mater using cyanoacrylate adhesive and dental acrylic and the animals were placed back into their home cages where they were closely monitored during the recovery process.

24 hours after the preparatory procedure was complete the animals were anesthetized using 4% isoflurane in order for the scalp to be incised to reveal the syringe hub. The group of test subjects that were assigned to one of the injured experimental groups were connected to an injury device in order for the injury to be delivered. Sham injury groups followed the same procedure, however the injury device was never activated, therefore no injury was delivered to the animals. The incision was closed and the animals returned to their home cage where they were monitored and provided free access to food and water. The primary outcome measures assessed post-injury were the right responses and Morris water maze performance due to the association between fluid percussion injury and various cognitive deficits and neurological impairments, such as areflexia, stupor, and unconsciousness [1].

First, the righting response was used to measure post traumatic unconsciousness in the test subjects as it is a complex postural somatic motor reflex that is typically repressed for several minutes following induction of a traumatic brain injury. The animal was placed on their back and the researchers recorded the amount of time it took for them to right themselves following the injury. Additionally, cognitive functioning was measured through the Morris water maze test. A clear platform was placed in 1 of the 4 quadrants in the testing apparatus which was then filled up with water until the top of the platform was hidden to the rats. 4 testing trials with 4 minute intertrial intervals took place on days 11-15 after induction of brain injury in order to allow for the recovery of any residual motor deficits [1].

The trial began by placing the rat in the pool facing the wall in one of the four start locations: north, south, east, and west and were given 120 seconds to find the hidden platform. A computerized tracking program was utilized to record the activity of the animals and the amount of time it took for them to reach the platform. The program also measured the distance from the rat to the platform during each trail and added together the distance measured at 0.2 second intervals to calculate the “cumulative distance from the goal” [1]. This was defined as how close each animal was swimming to the platform throughout the trial. The researchers mentioned that they also tracked the swim speed of the animals during each trial in order to detect the presence of any lasting motor impairments.

2) The assessment of eyeblink classical condition in rabbits is useful to make inferences regarding learning, memory, and aging as these behavioral and neurobiological impairments are hallmarks of Alzheimer’s disease. Alzheimer’s disease is also characterized by dementia related to the neuropathological loss of neurons and accumulation of amyloid-containing plaques and neurofibrillary tangles. Similar pathology has been observed in autopsies of individuals over the age of 35 with Down’s syndrome; this is a condition referred to as Down’s Syndrome/Alzheimer’s disease (DS/AD).

Previous research shows that the development of Alzheimer’s disease is correlated with impaired eyeblink classical conditioning more than the typical impairments seen with aging. It is interesting to note that adults with DS/AD similarly performed poorly during eyeblink classical conditioning, however adults with Down’s syndrome scored significantly higher than individuals with DS/AD or Alzheimer’s disease. Deficits seen in eyeblink classical conditioning related to Alzheimer’s disease indicate that there is a potential disruption in the functioning of cholinergic systems within the hippocampus. That being said, Alzheimer’s disease seemingly affects hippocampal functioning by disturbing cholinergic innervation of both cortical and hippocampal neurons, resulting in a longer acquisition rate of eyeblink classical conditioning. To identify potential treatment for these impairments, nefiracetam was used due to its proposed ability to promote the release of various neurotransmitters that may facilitate normal hippocampal functioning [2] .

Researcher Diana S. Woodruff-Pak hypothesized that nefiracetam affects eyeblink classical conditioning by improving functioning in the hippocampal pyramidal cells. That being said, administration with the nootropic should improve eyeblink classical conditioning in animals with an intact hippocampus, but will elicit no changes in animals where the hippocampus had been removed. 56 specific pathogen free (SPF) female New Zealand retired breeder rabbits were included in experiment 1 and an additional 11 SPF rabbits with verified lesions were included in experiment 2. The mean age of the rabbits included in experiment 1 was 27.9 months old while the average age of the rabbits included in experiment 2 was 26.8 months old. All animals were maintained under standard laboratory conditions and allowed free access to rabbit chow and tap water [2].

A restraining contraption was used to restrain each rabbit during the eyeblink classical conditions. Retractors held the left eye open while a removable platform holding the heastage in place was secured to the animals’ muzzle behind the ears. The headstage was positioned 1 cm away from the cornea and an unconditioned stimulus was presented through the airpuff. Nictitating membrane (NM) movement measurements were also collected through a minitorque potentiometer attached onto the headstage by a level and a lead to a nylon suture in the NM. The potentiometer on the head mount converted the NM movements into electrical signals that underwent analog-to-digital analysis. Collected values were analyzed immediately after each training session and stored for further examination [2].

The rabbits were restrained as previously described, in order to conduct both training sessions and drug injections. For the purpose of the training sessions, the animals were subcutaneously injected with nefiracetam or a vehicle 15 minutes before training began. The rabbits were then placed into the restrainer, fitted with the head mount, and positioned in a ventilated and sound-proofed experimental chamber where a conditioned stimulus was delivered in combination with the unconditioned stimulus, a corneal airpuff.

The conditioned stimulus was an 850 ms, 85 dB, and 1 kHz sound, followed by the delivery of a 100 ms, 3 psi corneal airpuff, 750 ms later. Delivery of both the conditioned stimulus and the corneal airpuff were terminated at the same time with a random inter-trial interval lasting from 10-20 seconds. The full session lasted 35-45 minutes and training was complete within an hour after nefiracetam or the vehicle was administered. During the trial, a conditioned response was automatically scored by the computer system if movement of the nictitating membrane took place between 25-750 ms after the onset of the conditioned stimulus, as well as if the movement was greater than 0.5 mm [2].

For the first experiment that took place, 64 rabbits with an intact hippocampus were included in daily acquisition sessions that included 90 trials pairing the conditioned stimulus of the sound and the unconditioned stimulus of the airpuff. Nefiracetam was dissolved in sterile saline and subcutaneously injected in doses of 1 mg/kg, 3 mg/kg, 5 mg/kg, 10 mg/kg, and 15 mg/kg. For the second experiment, 11 rabbits that were histologically confirmed to have bilateral surgical removal of the hippocampus were included in the study, while an additional 20 rabbits underwent a surgical procedure to produce aspiration lesions in aseptic surgical conditions [2].

The rabbits that underwent surgery to produce aspiration lesions were allowed to recover for 3 weeks before all of the test subjects went through further conditioning trials. Nefiracetam was dissolved in sterile saline and delivered to the animals in doses of 0 mg/kg and were given saline only, or 10 mg/kg. The eyeblink classical conditioning acquisition trials were carried out following the same methods as the previous experiments. Performance in the rabbits that underwent hippocampectomy was compared to those that received an injection of sterile saline, and those that received a 10 mg/kg dose of nefiracetam [2].

 

Discussion

1) The results of the righting reflex assessment performed by the research team of DeFord et al found that animals that underwent the induction of traumatic brain injury experienced a significantly longer suppression of the right response in comparison to the groups that underwent a sham injury. These results suggest that injury severity amongst the injured groups were equivalent.

Figure 1: The effects of traumatic brain injury on the length of time the righting reflex was suppressed in each experimental treatment group .

As for the results of the Morris water maze test a short goal latency was indicative of better performance and response to treatment. It was reported that the animals injured and treated with both 3 mg/kg and 9 mg/kg of nefiracetam had significantly shorter goal latencies in comparison to the injured animals that were treated with saline. Additionally, there were no significant differences between the sham groups or the uninjured control groups and those treated with 9 mg/kg of nefiracetam. These findings indicate that treatment with the nootropic has the potential to recover goal latencies to a level similar to baseline [1].

Figure 2: The effects of traumatic brain injury on the goal latencies of the experimental treatment groups subjected to Morris water maze testing on days 11-15 post-injury.

As it was previously mentioned, the researchers used the activity tracking program to measure the “cumulative distance from the goal,” defined as the distance each animal was from the platform during the trial. Lower scores indicate a better performance. Similar to the reported results of goal latencies, the cumulative distance of the animals injured and treated with both 3 mg/kg and 9 mg/kg of nefiracetam were significantly lower in comparison to the injured animals that were treated with saline. Additionally, there were no significant differences between the scores of the sham groups and those treated with 9 mg/kg of nefiracetam. These findings indicate that treatment with the nootropic has the potential to recover cumulative distances from the platform to a level similar to baseline [1].

Figure 3: The effects of traumatic brain injury on the cumulative distance from the platform recorded across the experimental treatment groups that underwent the Morris water maze test.

In regards to the swimming speed of the animals, single-factor ANOVA reported that there were no remarkable differences in swimming speed exhibited between the experimental groups. These findings suggested to the researchers that the measured differences in goal latency and cumulative distance from the platform were not related to injury-induced motor impairments or adverse effects of the drug treatment [1].

2) The study conducted by Woodruff-Pak examined how administration of nefiracetam affects eyeblink classical conditioning in rabbits with an intact hippocampus and in those with their hippocampus removed bilaterally. Two experiments were conducted, the first of which included 64 intact rabbits administered varying doses of the nootropic including 1, 3, 5, 10, and 15 mg/kg. The second experiment included 11 rabbits that had their hippocampus removed and 20 rabbits that underwent surgery to produce aspiration lesions on the hippocampus. They were then treated with either sterile saline or 10 mg/kg of nefiracetam [2].

The initial results of the first experiment found that in the rabbits administered nefiracetam there was a significant improvement in the amount of time it took to learn the association between the stimuli delivered, in comparison to the rabbits that were treated only with a vehicle. The improved learning times are indicative of enhanced cognitive functioning; the dose that was shown to be most effective was 10 mg/kg of nefiracetam. It was also found that the amplitude of the unconditioned response was affected most significantly with 3 mg/kg doses of nefiracetam, in comparison to the animals treated with a vehicle. It is important to mention that in the rabbits administered 10 mg/kg of the nootropic, the average amplitude of the unconditioned response was comparable to the rabbits treated with a vehicle. The amplitude in the 10 mg/kg treatment group was recorded as 4.38 mm while the amplitude in the vehicle treated group was recorded as 5.00 mm [2]. This was despite the previous findings that reported the 10 mg/kg dose of nefiracetam attenuates learning deficits and improves cognitive functioning.

Figure 3: The number of trials it took for the older rabbits included in each experimental treatment group to learn the association between the unconditioned stimulus and conditioned stimulus.

The results of the second experiment conducted including hippocampectomized rabbits found that there was a significantly better rate of leaning in intact older rabbits administered 10 mg/kg of nefiracetam, compared to those treated with a vehicle. That being said, treatment with 10 mg/kg of nefiracetam did not elicit any significant effects on learning in the hippocampectomized rabbits. These findings supported the hypothesis developed by Woodruff-Pak that treatment with the nootropic did not affect cognitive functioning in rabbits that did not have a hippocampus but improved it in rabbits that remained intact. This indicates that the mechanism of action that drives the benefits of nefiracetam is associated with the hippocampal pyramidal cells [2].

Figure 4: The number of trials it took for hippocampectomized and intact rabbits from each experimental treatment group to learn the association between the unconditioned stimulus and conditioned stimulus.

The overall results of both experiment 1 and 2 suggest that 10 mg/kg of nefiracetam had the potential to reduce the number of trials it took for aged rabbits to learn the association between an unconditioned and conditioned stimulus delivered during eyeblink classical conditioning testing. Additionally, this dose was only effective in the rabbits that did not have their hippocampus removed, indicating that the nootropic works to attenuate eyeblink classical conditioning by acting on the cells of the hippocampus. Specifically, the CA1 pyramidal neurons are most affected by aging with adult animals losing 15-20% of these cells [2].

That being said, nefiracetam has been shown to have the potential to protect membrane dysfunction in hippocampal CA1 neurons after episodes of glucose and oxygen deprivation. Additionally, nefiracetam may combat learning deficits in older animals by enhancing the function of the hippocampal CA1 pyramidal neurons that are still remaining. It is important to mention that the results regarding the effects of nefiracetam were supported by research focused on another cognition enhancing supplement, nimodipine. The findings suggest that the improvement of deficits in eyeblink classical conditioning in older rabbits is related to the facilitation of hippocampal pyramidal neuron functioning [2].

 

Disclaimer

**LAB USE ONLY**
*This information is for educational purposes only and does not constitute medical advice. THE PRODUCTS DESCRIBED HEREIN ARE FOR RESEARCH USE ONLY. All clinical research must be conducted with oversight from the appropriate Institutional Review Board (IRB). All preclinical research must be conducted with oversight from the appropriate Institutional Animal Care and Use Committee (IACUC) following the guidelines of the Animal Welfare Act (AWA).

 

Citations

[1] DeFord SM, Wilson MS, Gibson CJ, Baranova A, Hamm RJ. Nefiracetam improves Morris water maze performance following traumatic brain injury in rats. Pharmacol Biochem Behav. 2001 Jul-Aug;69(3-4):611-6. doi: 10.1016/s0091-3057(01)00559-7. PMID: 11509223.

[2] Woodruff-Pak DS. Nefiracetam ameliorates learning deficits in older rabbits and may act via the hippocampus. Behav Brain Res. 1997 Feb;83(1-2):179-84. doi: 10.1016/s0166-4328(97)86065-2. PMID: 9062680.

Mechanisms of Action of Nefiracetam

Nefiracetam is a nootropic compound of the racetam group. Nefiracetam is derived from another popular nootropic, piracetam. While it is derived from piracetam, nefiracetam is most structurally similar to aniracetam. Both of these compounds are considered fat soluble and are most commonly used for enhancing cognition and improving memory. Like many other racetam compounds, nefiracetam is not usually effective with just one dose. Improved memory formation tends to be observed when nefiracetam is administered for longer than 7 days. Prolonged supplementation of the compound also tends to lead to neurogenesis and assists in facilitating cognitive enhancement.

Currently there are two proposed mechanisms of action for nefiracetam. The first pathway is the prolonged opening of calcium channels. This results in an enhanced receptor signaling that is independent of the synapse. The second pathway is related to the activity of protein kinase C (PKC) and calcium calmodulin-dependent protein kinase II (CaMKII). This pathway leads to the augmentation of cholinergic receptor signaling and results in the release of excitatory neurotransmitters from the presynaptic level. There are benefits to both pathways. For example, the opening of calcium channels is crucial for long term potentiation while the PKC/CaMKII pathway is important for the enhancement of neuronal signaling.

 

Effects of Nefiracetam on Neurotransmission Systems

Nefiracetam has been shown to be capable of regulating the actions of many of the main neurotransmitters in the brain. A multitude of animal-based studies have been conducted examining how the effects of nefiracetam are dependent on cholinergic signaling and acetylcholine (ACh) release. A notable study conducted on rabbits identified improved performance on delayed eye blinking conditions. Researchers Pak et. Al were able to determine that results of this test are dependent on cholinergic signaling in the hippocampus. Since nefiracetam is dependent on the hippocampus in this study, they came to the conclusion that the cognitive enhancing effects of nefiracetam are related to cholinergic signaling.

Additional studies mentioned how the memory improvement effects of nefiracetam seem to depend on ACh signaling in cases of protein synthesis inhibition. Researchers Nabeshima et. Al observed how the effects of nefiracetam can be reversed through administration of scopolamine. This mechanism of action allowed them to hypothesize that the anti-amnesiac effects of nefiracetam could potentially be related to muscarinic acetylcholine receptors. Follow up studies implemented a passive avoidance test for mice where amnesia was induced through the inhibition of protein synthesis. The results of the study found that proper release of ACh proved to be protective against induced amnesia. Nefiracetam can assist in this effort as it has shown potential in preserving ACh levels.

Evidence has noted that nefiracetam seems to activate presynaptic acetylcholine receptors in the hippocampus, resulting in an increase in glutamate release. The enhanced glutaminergic effect leads to more postsynaptic activity as well as the activation of NMDA and AMPA receptors. Because nefiracetam has the ability to increase glutamate release, reports show the nootropic plays a role in improving long term potentiation (LTP). Through the PKC mechanism, low concentrations of the compound enhance LTP that is dependent on NMDA receptors and at high concentrations it enhances LTP dependent on AMPA receptors. Pairing this knowledge with the effects nefiracetam has on the cholinergic system, researchers conclude that the compound effectively recruits both of the major stimulatory neurotransmitters, ACh and glutamate.

Nefiracetam has also shown promise in its ability to regulate functioning of GABA and GABA A receptors. Despite the lack of affinity for the GABA binding sites, reports show that nefiracetam is capable of enhancing the signaling to these receptors when concentrations of GABA are low. When GABA concentrations are high the opposite effect is observed meaning that signaling is suppressed.

Researchers Luthman et. Al discovered that nefiracetam plays a more covert role on the serotonergic system. Their study suggests that doses varying from 10-30 mg/kg of nefiracetam are effective at counteracting the loss of serotonin due to induced ischemia. Additional research has found that in doses ranging from 3-10 mg/kg given 30 minutes after administration of a serotonergic antagonist led to an improvement in performance on various choice recognition tasks.

Similar results were seen when examining the effects of nefiracetam on the dopaminergic system. However, the results varied between studies and benefits were only seen when high doses of the compound were administered. Further research needs to be conducted in order to come to a strong conclusion regarding the relationship between nefiracetam and dopamine levels (https://examine.com/supplements/nefiracetam/research/#RQbokJY-neurology-1_RQbokJY-g-protein-and-calcium-signalling-1).

The nootropics sold by Umbrella Labs are sold for laboratory research only. The description above is not medical advice and is for informative purposes only.

Nefiracetam is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms & Conditions prior to ordering.

 

 

File Name	View/Download
09-05-2023-Umbrella-Labs-Nefiracetam-Certificate-of-Analysis-COA.pdf

 

 

VIEW CERTIFICATES OF ANALYSIS (COA)